Immunovant, Inc. (IMVT) vs Ionis Pharmaceuticals, Inc. (IONS)
A side-by-side comparison of Immunovant, Inc. and Ionis Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMVT
Immunovant, Inc.
$32.58HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
IONS
Ionis Pharmaceuticals, Inc.
$44.39HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
Total return — IMVT vs IONS
growth of $100 · dividends reinvested · last 7yIMVT +234.2% (+18.8%/yr)IONS -33.3% (-5.6%/yr)IMVT compounded faster over this window
Log scale — wide-divergence pair
IMVT IONS
IMVT vs IONS: by the numbers
- •IONS is the larger company ($7.38B vs $6.72B market cap).
- •Both run net losses; IONS's is the smaller (-64.64% vs -7585.86% net margin).
Metrics side by side
Valuation
| Metric | IMVT | IONS |
|---|---|---|
| P/S ratio | 947.79 | 8.44 |
| P/B ratio | 9.14 | 16.77 |
| EV / EBITDA | N/A | 2.23 |
Profitability
| Metric | IMVT | IONS |
|---|---|---|
| Gross margin | 0.00% | 98.16% |
| Operating margin | 0.00% | -40.47% |
| Net margin | -7585.86% | -64.64% |
| ROE | -73.19% | -128.44% |
| ROIC | -76.00% | -20.37% |
Growth (annualized)
| Metric | IMVT | IONS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 4.91% |
| Total return CAGR (5Y) | 29.93% | 5.82% |
Frequently asked
- How have IMVT and IONS total returns compared?
- Over the past 5 years, IMVT delivered 29.93% and IONS delivered 5.82% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.